European Radiology

, Volume 27, Issue 5, pp 2031–2041 | Cite as

Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus 90Y-radioembolization for hepatocellular carcinoma

  • Johannes M. Ludwig
  • Di Zhang
  • Minzhi Xing
  • Hyun S. Kim
Oncology

Abstract

Objective

To investigate comparative effectiveness of drug-eluting bead transarterial chemoembolization (DEB-TACE) versus Yttrium-90 (90Y)-radioembolization for hepatocellular carcinoma (HCC).

Methods

Studies comparing conventional (c)TACE versus 90Y-radioembolization or DEB-TACE for HCC treatment were identified using PubMed/Medline, Embase, and Cochrane databases. The adjusted indirect meta-analytic method for effectiveness comparison of DEB-TACE versus 90Y-radioembolization was used. Wilcoxon rank-sum test was used to compare baseline characteristics. A priori defined sensitivity analysis of stratified study subgroups was performed for primary outcome analyses. Publication bias was tested by Egger’s and Begg’s tests.

Results

Fourteen studies comparing DEB-TACE or 90Y-radioembolization with cTACE were included. Analysis revealed a 1-year overall survival benefit for DEB-TACE over 90Y-radioembolization (79 % vs. 54.8 %; OR: 0.57; 95 %CI: 0.355-0.915; p = 0.02; I-squared: 0 %; p > 0.5), but not for the 2-year (61 % vs. 34 %; OR: 0.65; 95%CI: 0.294-1.437; p = 0.29) and 3-year survival (56.4 % vs. 20.9 %; OR: 0.713; 95 % CI: 0.21-2.548; p = 0.62). There was significant heterogeneity in the 2- and 3-year survival analyses. The pooled median overall survival was longer for DEB-TACE (22.6 vs. 14.7 months). There was no significant difference in tumour response rate.

Conclusion

DEB-TACE and 90Y-radioembolization are efficacious treatments for patients suffering from HCC; DEB-TACE demonstrated survival benefit at 1-year compared to 90Y-radioembolization but direct comparison is warranted for further evaluation.

Key Points

This meta-analysis shows greater 1-year survival benefit for DEB-TACE over 90 Y-radioembolization.

DEB-TACE has a favourable 2- & 3-year survival benefit trend over 90 Y-radioembolization.

No significant difference for tumour response was detected.

Direct comparison of these methods for a more robust evaluation is warranted.

Keywords

Interventional Radiology Meta-Analysis Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE) Yttrium-90 Radioembolization Hepatocellular Carcinoma 

Abbreviations

HCC

Hepatocellular Carcinoma

BCLC

Barcelona Clinic Liver Cancer

TACE

Transarterial Chemoembolization

cTACE

convectional Transarterial Chemoembolization

90Y

Yttrium-90

DEB-TACE

Drug-Eluting-Bead Transarterial Chemoembolization

RCT

Randomized Controlled Trial

OS

Overall Survival

CR

Complete tumour Response

PR

Partial tumour Response

AE

Adverse Events

OR

Odds Ratio

mRECIST

modified Response Evaluation Criteria in Solid Tumours

CI

Confidence Interval

RECIST

Response Evaluation Criteria in Solid Tumours

WHO

World Health Organization

EASL

European Association for the Study of the Liver

AFP

Alpha-1-Fetoprotein

PVT

Portal Vein Thrombosis

Notes

Acknowledgments

The scientific guarantor of this publication is: Dr Hyun S. Kim. The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article. The authors state that this work has not received any funding. One of the authors has significant statistical expertise. (Co-author: Zhang, Di). Institutional review board approval was not required because of literature-based research. Methodology: Meta-Analysis

References

  1. 1.
    Howlader N, Noone A, Krapcho M et al (2013) SEER cancer statistics review, 1975-2011. National Cancer Institute, Bethesda, MD. Available via http://seer.cancer.gov/csr/1975_2011/. Accessed 17 Nov 2014
  2. 2.
    Ferlay J, Soerjomataram I, Dikshit R et al (2014) Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. doi: 10.1002/ijc.29210 PubMedGoogle Scholar
  3. 3.
    Khan AS, Fowler KJ, Chapman WC (2014) Current surgical treatment strategies for hepatocellular carcinoma in North America. World J Gastroenterol 20:15007–15017CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56:908–943CrossRefGoogle Scholar
  5. 5.
    Forner A, Llovet JM, Bruix J (2012) Hepatocellular carcinoma. Lancet 379:1245–1255CrossRefPubMedGoogle Scholar
  6. 6.
    Boulin M, Hillon P, Cercueil JP et al (2014) Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial. Aliment Pharmacol Ther 39:1301–1313CrossRefPubMedGoogle Scholar
  7. 7.
    Abdel-Rahman O, Elsayed ZA (2013) Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature. Dig Dis Sci 58:3389–3396CrossRefPubMedGoogle Scholar
  8. 8.
    Fong ZV, Tanabe KK (2014) The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: a comprehensive and evidence-based comparison and review. Cancer 120:2824–2838CrossRefPubMedGoogle Scholar
  9. 9.
    Varela M, Real MI, Burrel M et al (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46:474–481CrossRefPubMedGoogle Scholar
  10. 10.
    Huang K, Zhou Q, Wang R, Cheng D, Ma Y (2013) Doxorubicin-eluting bead versus conventional transarterial chemoembolization for the treatment of HCC: a meta-analysis (Provisional abstract). J Gastroenterol HepatolGoogle Scholar
  11. 11.
    Vente MAD, Wondergem M, van der Tweel I et al (2009) Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: A structured meta-analysis. Eur Radiol 19:951–959CrossRefPubMedGoogle Scholar
  12. 12.
    Murthy R, Kamat P, Nunez R, Salem R (2008) Radioembolization of yttrium-90 microspheres for hepatic malignancy. Semin Interv Radiol 25:48–57CrossRefGoogle Scholar
  13. 13.
    Xing M, Kokabi N, Camacho JC, Kooby DA, El-Rayes BF, Kim HS (2013) 90Y radioembolization versus chemoembolization in the treatment of hepatocellular carcinoma: an analysis of comparative effectiveness. J Comp Eff Res 2:435–444CrossRefPubMedGoogle Scholar
  14. 14.
    Pitton MB, Kloeckner R, Ruckes C et al (2014) Randomized Comparison of Selective Internal Radiotherapy (SIRT) Versus Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE) for the Treatment of Hepatocellular Carcinoma. Cardiovasc Intervent Radiol. doi: 10.1007/s00270-014-1012-0 PubMedPubMedCentralGoogle Scholar
  15. 15.
    Seinstra BA, Defreyne L, Lambert B et al (2012) Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial. Trials 13:144CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Golfieri R, Giampalma E, Renzulli M et al (2014) Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 111:255–264CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Recchia F, Passalacqua G, Filauri P et al (2012) Chemoembolization of unresectable hepatocellular carcinoma: Decreased toxicity with slow-release doxorubicineluting beads compared with lipiodol. Oncol Rep 27:1377–1383PubMedGoogle Scholar
  18. 18.
    Song MJ, Chun HJ, do Song S et al (2012) Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol 57:1244–1250CrossRefPubMedGoogle Scholar
  19. 19.
    Sacco R, Bargellini I, Bertini M et al (2011) Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 22:1545–1552CrossRefPubMedGoogle Scholar
  20. 20.
    Ferrer Puchol MD, la Parra C, Esteban E et al (2011) Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma. Radiologia 53:246–253CrossRefPubMedGoogle Scholar
  21. 21.
    Wiggermann P, Sieron D, Brosche C et al (2011) Transarterial Chemoembolization of Child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs. TACE with cisplatin/lipiodol (cTACE). Med Sci Monit 17:CR189–CR195CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS (2010) Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). J Surg Oncol 101:476–480PubMedGoogle Scholar
  23. 23.
    Kolligs FT, Bilbao JI, Jakobs T et al (2014) Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. Liver Int. doi: 10.1111/liv.12750 PubMedGoogle Scholar
  24. 24.
    El Fouly A, Ertle J, El Dorry A et al (2015) In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? Liver Int 35:627–635CrossRefPubMedGoogle Scholar
  25. 25.
    Moreno-Luna LE, Yang JD, Sanchez W et al (2013) Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol 36:714–723CrossRefPubMedGoogle Scholar
  26. 26.
    Salem R, Lewandowski RJ, Kulik L et al (2011) Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 140:497–507, e492CrossRefPubMedGoogle Scholar
  27. 27.
    Lance C, McLennan G, Obuchowski N et al (2011) Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol 22:1697–1705CrossRefPubMedGoogle Scholar
  28. 28.
    Kooby DA, Egnatashvili V, Srinivasan S et al (2010) Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 21:224–230CrossRefPubMedGoogle Scholar
  29. 29.
    Carr BI, Kondragunta V, Buch SC, Branch RA (2010) Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer 116:1305–1314CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5:13CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188CrossRefPubMedGoogle Scholar
  32. 32.
    Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558CrossRefPubMedGoogle Scholar
  33. 33.
    Bucher HC, Guyatt GH, Griffith LE, Walter SD (1997) The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 50:683–691CrossRefPubMedGoogle Scholar
  34. 34.
    Sacks D, McClenny TE, Cardella JF, Lewis CA (2003) Society of interventional radiology clinical practice guidelines. J Vasc Interv Radiol 14:S199–S202CrossRefPubMedGoogle Scholar
  35. 35.
    Salem R, Lewandowski RJ, Gates VL et al (2011) Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol 22:265–278Google Scholar
  36. 36.
    Sangro B, Salem R (2014) Transarterial chemoembolization and radioembolization. Semin Liver Dis 34:435–443CrossRefPubMedGoogle Scholar
  37. 37.
    Salem R, Lewandowski RJ, Mulcahy MF et al (2010) Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 138:52–64CrossRefPubMedGoogle Scholar
  38. 38.
    Gorodetski B, Chapiro J, Schernthaner R et al (2016) Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization. Eur Radiol. doi: 10.1007/s00330-016-4445-9 PubMedGoogle Scholar
  39. 39.
    Salem R, Gilbertsen M, Butt Z et al (2013) Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol 11:1358–1365, e1351CrossRefPubMedGoogle Scholar
  40. 40.
    Prajapati HJ, Rafi S, El-Rayes BF, Kauh JS, Kooby DA, Kim HS (2012) Safety and feasibility of same-day discharge of patients with unresectable hepatocellular carcinoma treated with doxorubicin drug-eluting bead transcatheter chemoembolization. J Vasc Interv Radiol 23:1286–1293, e1281CrossRefPubMedGoogle Scholar
  41. 41.
    Song F, Altman DG, Glenny AM, Deeks JJ (2003) Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 326:472CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Glenny AM, Altman DG, Song F et al (2005) Indirect comparisons of competing interventions. Health Technol Assess 9:1–134, iii-ivCrossRefPubMedGoogle Scholar
  43. 43.
    Cornell JE (2014) Random-effects meta-analysis of inconsistent effects. In response. Ann Intern Med 161:380CrossRefPubMedGoogle Scholar
  44. 44.
    Chiappelli F, Brant XMC, Neagos N, Oluwadara OO, Ramchandani MH (2010) Evidence-based practice: toward optimizing clinical outcomes. Springer, Berlin HeidelbergCrossRefGoogle Scholar

Copyright information

© European Society of Radiology 2016

Authors and Affiliations

  • Johannes M. Ludwig
    • 1
  • Di Zhang
    • 2
  • Minzhi Xing
    • 1
  • Hyun S. Kim
    • 1
    • 3
  1. 1.Division of Interventional Radiology, Department of Radiology and Biomedical ImagingYale School of MedicineNew HavenUSA
  2. 2.Department of BiostatisticsUniversity of Pittsburgh Graduate School of Public HealthPittsburghUSA
  3. 3.Yale Cancer CenterYale School of MedicineNew HavenUSA

Personalised recommendations